Skip to main content

Table 1 Clinical results at 1 year in major randomized trials with coronary stenting

From: Long-term outcome after coronary stenting

   Angiographic restenosis      
Study/Procedure n rate (%) Death (%) MI (%) CABG (%) PTCA (%) MACE (%)
BENESTENT [13,17]        
   Stent 259 22* 1.2 3.5 6.9 10.0* 23.2*
   PTCA 257 32 0.8 1.9 5.1 20.6 31.5
STRESS [14,38]        
   Stent 205 32* 1.5 3.4 5.8 15.1 21.0
   PTCA 202 42 2.0 3.5 8.9 16.4 26.2
BENESTENT II [35]        
   Stent (heparin coated) 413 16* 1.0 1.9 1.9 9.4* 15.7*
   PTCA 410 31 1.0 1.5 1.5 15.6 22.4
EPISTENT [11]        
   Stent + abciximab 794 31 1.0 4.4 5.8 13.6* 18.6*
   PTCA + abciximab 796 40 2.1 6.4 6.3 18.3 24.9
ARTS [39]        
   Stent 600 N/A 2.5 5.3 4.7* 12.2* 26.3*
   CABG 605 N/A 2.8 4.0 0.5 3.0 12.2
  1. Study acronyms are defined in the text. *P < 0.05 for the comparison between stent and respective control arm (PTCA or CABG). Restenosis data presented at the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, 1999. MACE, any major adverse clinical event; MI, myocardial infarction (defined as either Q-wave infarction or creatine kinase elevation ≥ 5 times the upper normal limit); N/A, not available.